We use essential cookies and third-party cookies for content.

Arizona Tribune - NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

Arizona Tribune
×
NYSE - LSE
RBGPF 0% 68.32 $
CMSC -0.36% 21.98 $
VOD -0.23% 13.05 $
NGG 0.63% 83.11 $
BTI 0.55% 61.8 $
RELX 1.65% 32.81 $
RYCEF -3.22% 19.28 $
BP 3.16% 38.61 $
RIO -2.55% 91.25 $
GSK 0.43% 53.32 $
AZN 1.53% 193.12 $
BCE 2.48% 21.4 $
BCC -2.56% 73.4 $
CMSD -0.18% 22.19 $
JRI -0.08% 13.1 $
NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event
NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event

ECONOMY 11.11.2024

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Q4 Investor Summit. The company will be available for 1-on-1 meetings throughout the day in addition to its presentation.

Text size:

Event: Q4 Investor Summit
Presentation Time: 11:00am - 11:30am ET
Location: https://www.webcaster4.com/Webcast/Page/3075/51588

  • The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.

  • Take a deep dive with the best Investors in MicroCap

  • Live Q & A

  • Complimentary to Qualified Investors. Please REGISTER HERE.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.neurobopharma.com.

About the Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.

Contact:
Fred Rockwell
[email protected]
Investor Summit Group

SOURCE: NeuroBo Pharmaceuticals, Inc.

R.Garcia--AT

Featured

OpenAI to launch new model after US freeze

OpenAI to launch new model after US freeze
US, Iran trade strikes in new threat to ceasefire

US, Iran trade strikes in new threat to ceasefire
Chinese repairwomen smash stereotypes with power tools

Chinese repairwomen smash stereotypes with power tools
'Unique event': Solar eclipse fever fills empty Spain

'Unique event': Solar eclipse fever fills empty Spain